Ovarian Cancer Clinical Trial
Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
Summary
The primary objective is to evaluate in participants with high-grade serous ovarian cancer (HGSOC), whether the reduction from baseline in circulating tumor DNA (ctDNA) at Cycle 3 (ΔctDNA) is larger in participants receiving MK-4830 + pembrolizumab in combination with standard of care (SOC) therapy than in those receiving pembrolizumab + SOC therapy.
Eligibility Criteria
The main inclusion and exclusion criteria include but are not limited to the following:
Inclusion Criteria:
Has histologically-confirmed International Federation of Gynecology and Obstetrics (FIGO) Stage III or Stage IV HGSOC, primary peritoneal cancer, or fallopian tube cancer.
Is a candidate for carboplatin and paclitaxel chemotherapy, to be administered in the neoadjuvant and adjuvant setting.
Is a candidate for interval debulking surgery.
Is able to provide archival tissue or newly obtained core, incisional, or excisional biopsy of a tumor lesion.
Has adequate organ functions.
Exclusion Criteria:
Has a non-HGSOC histology.
Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
Has received prior treatment for any stage of OC, including radiation or systemic anticancer therapy.
Planned or has been administered intraperitoneal chemotherapy as first-line therapy.
Has received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-programmed cell death 1 ligand 1 (PD-L1), anti-programmed cell death 1 ligand 2 (PD-L2), anti-immunoglobulin-like transcript 4 (ILT4), or anti-human leukocyte antigen (HLA)-G agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor.
Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention.
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication.
Has known active Central Nervous System (CNS) metastases and/or carcinomatous meningitis.
Has severe hypersensitivity to pembrolizumab, carboplatin, paclitaxel (or docetaxel, if applicable), Avastin or biosimilar (if using) and/or any of their excipients.
Has an active autoimmune disease that has required systemic treatment in past 2 years.
Has an active infection requiring systemic therapy.
Has a known history of human immunodeficiency virus (HIV) infection.
Has a known history of hepatitis B or known active hepatitis C virus infection.
Has received colony-stimulating factors within 4 weeks prior to receiving study intervention on Day 1 of Cycle 1.
Has had surgery <6 months prior to Screening to treat borderline ovarian tumors, early-stage OC, or early-stage fallopian tube cancer.
Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
Has current, clinically relevant bowel obstruction.
Has a history of hemorrhage, hemoptysis, or active gastrointestinal (GI) bleeding within 6 months prior to randomization.
Has uncontrolled hypertension.
Has had an allogenic tissue/solid organ transplant.
.Has either had major surgery within 3 weeks of randomization or has not recovered from any effects of any major surgery.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 40 Locations for this study
Aurora Colorado, 80045, United States More Info
New Brunswick New Jersey, 08903, United States More Info
Mineola New York, 11501, United States More Info
New York New York, 10016, United States More Info
New York New York, 10065, United States More Info
Sioux Falls South Dakota, 57104, United States More Info
Montréal Quebec, H2X 3, Canada More Info
Santiago Region M. De Santiago, 83300, Chile More Info
Napoli Campania, 80131, Italy More Info
Roma Lazio, oo168, Italy More Info
Milan Lombardia, 20133, Italy More Info
Milano , 20141, Italy More Info
Siedlce Mazowieckie, 08-11, Poland More Info
Warszawa Mazowieckie, 02-78, Poland More Info
Gdańsk Pomorskie, 80-21, Poland More Info
Kielce Swietokrzyskie, 25-73, Poland More Info
Poznan Wielkopolskie, 61-84, Poland More Info
Singapore Central Singapore, 16961, Singapore More Info
Madrid Madrid, Comunidad De, 28041, Spain More Info
Barcelona , 08035, Spain More Info
Changhua County Changhua, 50006, Taiwan More Info
How clear is this clinincal trial information?